Pinned
🚀 Announcing our new multi-year data license agreement with @GSK to investigate the drivers of #liverdisease!
Read the announcement ➡️
ochre-bio.com/2024/06/12/gsk…
Ochre Bio
@OchreBio
Breaking the silence of a top ten global killer: Chronic liver disease.
- For 10+ yrs, Susan’s blood tests has elevated liver enzymes, but told it was “nothing serious.” By the time symptoms hit, it was MASH. Liver disease often hides, thats why we’re working on direct-acting antifibrotic therapies to slow/reverse progression.
- Liver disease kills millions – yet there are far too few treatments. On The Pharma Letter Podcast, our CEO @QuinWills shares how we’re changing drug discovery: 🧬 Testing RNA therapeutics in human donor livers 🎯 Targeting fibrosis, cirrhosis & more 🎧 open.spotify.com/episode/10xOVk…
- Q2 commercial performance of the first approved MASH therapy shows impressive uptake. A shift toward GLP-1 combinations reflects the need for therapies targeting multiple mechanisms to help more patients respond & reverse fibrosis. 🔗endpoints.news/madrigals-mash…
- We’re revisiting CEO @QuinWills on @Citeline In Vivo podcast, where he spoke with David Wild about Ochre’s approach to liver disease. From testing RNA therapies in perfused human livers to why starting with human biology matters. Listen here ➡️ insights.citeline.com/in-vivo/podcas…
